RedHill Biopharma Ltd (納斯達克:RDHL) (特拉維夫股票交易所:RDHL) (“RedHill”或”公司”)是一家專業生物製藥公司，致力于後期臨床試驗階段胃腸疾病和炎症性疾病及癌症專有口服小分子藥物的開發和商業化。本公司今天公布了截至2017年3月31日的第一季度財務結果。
2017年第一季度末RedHill資産負債表上負債爲零，現金結餘$6100萬，使公司能够繼續努力落實開發計劃和美國商業化計劃。
部分近期重要事件如下：
未來幾個月預計將迎來的潜在重要事件：
RedHill首席財務官Micha Ben說道：“我們對2017年第一季度所取得的成績感到滿意，包括獲得兩款商業胃腸産品在美國市場的權利，這是RedHill在美國成爲創造營收的專注胃腸藥特殊醫藥公司戰略計劃的一部分，爲我們可能獲得批准的後期臨床階段研發綫藥品打下基礎。截至第一季度末公司現金頭寸$6100萬元，使我們可以繼續執行2017年戰略計劃，幷努力推進後期階段臨床項目。我們十分期待未來幾個月將發生的重要事件，包括BEKINDA®腸胃炎三期GUARD試驗發布試驗結果，啓動RHB-105幽門螺杆菌感染驗證性三期試驗，正在進行的RHB-104克羅恩病MAP美國三期試驗舉行第二次獨立數據和安全監測委員會會議，以及啓動Donnatal®和EnteraGam®在美國的推廣活動。”
電話會議和網絡直播信息：
公司將在今天（2017年5月3日（周三）美國東部時間上午9:00）召開電話會議，回顧財務結果和業務亮點。
參與電話會議，請在電話會議開始前提前15分鐘撥打：+1-877-280-2342（美國）、+1-212-444-0896（國際）、+972-3-763-0147（以色列）。會議代碼：1922788。
本次電話會議將在公司網站提供直播和重播，重聽有效期30天。請至少提前15分鐘登錄公司網站http://ir.redhillbio.com/events.cfm進行注册，下載幷安裝必要音頻軟件。
RedHill Biopharma Ltd介紹：
RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) 是一家總部位于以色列的專業生物醫藥公司，主要專注于開發幷銷售治療腸胃疾病和炎症性疾病以及癌症方面的處于後期臨床試驗階段的專有口服小分子藥。RedHill已與Concordia就Donnatal®簽署美國地區的聯合推廣協議，Donnatal®是一種用于治療腸易激綜合征和急性小腸結腸炎的處方口服輔助藥物。RedHill目前處于臨床階段的産品管綫包括：(i) RHB-105 -治療幽門螺杆菌感染的口服混合藥，首個三期試驗獲得成功；(ii) RHB-104 -治療克羅恩病的口服混合藥，正在進行首項三期試驗以及治療多發性硬化症的IIa期概念驗證試驗；(iii)BEKINDA™ (RHB-102) -日服一次的昂丹司瓊口服藥片製劑，正在美國進行治療急性腸胃炎和慢性胃炎的三期試驗，以及治療腹瀉型腸易激綜合征的二期試驗；(iv) RHB-106 -腸道準備藥物膠囊，已經授權給Salix Pharmaceuticals Ltd.；(v) YELIVA™ (ABC294640) -二期階段的口服SK2選擇性抑制劑，是首創新藥，靶向爲多種腫瘤、炎症性和胃腸道適應症；(vi) MESUPRON® -處于二期試驗階段的口服蛋白酶抑制劑，是首創新藥，靶向爲胃腸和其他實體瘤；(vii) RIZAPORT™ (RHB-103) -利扎曲坦口服薄膜製劑，用于治療急性偏頭痛，正在與美國食品藥品監督管理局討論新藥申請，2015年10月獲准在德國上市。欲瞭解與本公司有關的更多資訊，請訪問：www.redhillbio.com。
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to successfully market Donnatal®, (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; and (xii) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing; (xiii) competitive companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on February 23, 2017. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.
注：該新聞稿的唯一官方版本是本公司發布的英文原版稿件。本摘要和翻譯版本僅爲方便閱讀之目的。
公司聯絡人
Adi Frish
業務發展和許可高級副總裁
RedHill Biopharma
+972-54-6543-112
[email protected]
投資者關係聯絡人 （美國）
Marcy Nanus
高級副總裁
The Trout Group
+1-646-378-2927
[email protected]
